BACKGROUND: Platinum-based chemotherapy associated with cetuximab is the first-line treatment for inoperable recurrence or metastatic head and neck squamous cell carcinoma (HNSCC). There is no established biomarker for cetuximab efficacy in HNSCC. The PI3K pathway is one of the most frequently altered pathways in HNSCC. Loss of phosphatase and tensin homolog (PTEN) expression occurs in up to 30 % of cases. METHODS: This was a retrospective analysis of data from 61 patients with inoperable recurrence or metastatic HNSCC treated with cetuximab. PTEN, epidermal growth factor receptor and p16 expression were analyzed by immunohistochemistry and tested for association with clinical outcomes. RESULTS: Median overall survival was 11.4 months and progression-free survival was 6.9 months. Low PTEN expression was present in 26.2 % of patients and identified patients with worse prognosis. p16 was positive in only 8.5 % of tumors. CONCLUSIONS: Low PTEN expression in patients treated with cetuximab plus chemotherapy emerged as a prognostic biomarker and should be evaluated for its predictive role for cetuximab efficacy.
BACKGROUND:Platinum-based chemotherapy associated with cetuximab is the first-line treatment for inoperable recurrence or metastatic head and neck squamous cell carcinoma (HNSCC). There is no established biomarker for cetuximab efficacy in HNSCC. The PI3K pathway is one of the most frequently altered pathways in HNSCC. Loss of phosphatase and tensin homolog (PTEN) expression occurs in up to 30 % of cases. METHODS: This was a retrospective analysis of data from 61 patients with inoperable recurrence or metastatic HNSCC treated with cetuximab. PTEN, epidermal growth factor receptor and p16 expression were analyzed by immunohistochemistry and tested for association with clinical outcomes. RESULTS: Median overall survival was 11.4 months and progression-free survival was 6.9 months. Low PTEN expression was present in 26.2 % of patients and identified patients with worse prognosis. p16 was positive in only 8.5 % of tumors. CONCLUSIONS: Low PTEN expression in patients treated with cetuximab plus chemotherapy emerged as a prognostic biomarker and should be evaluated for its predictive role for cetuximab efficacy.
Authors: A A Forastiere; B Metch; D E Schuller; J F Ensley; L F Hutchins; P Triozzi; J A Kish; S McClure; E VonFeldt; S K Williamson Journal: J Clin Oncol Date: 1992-08 Impact factor: 44.544
Authors: Yoichi Nagata; Keng-Hsueh Lan; Xiaoyan Zhou; Ming Tan; Francisco J Esteva; Aysegul A Sahin; Kristine S Klos; Ping Li; Brett P Monia; Nina T Nguyen; Gabriel N Hortobagyi; Mien-Chie Hung; Dihua Yu Journal: Cancer Cell Date: 2004-08 Impact factor: 31.743
Authors: Vivian W Y Lui; Matthew L Hedberg; Hua Li; Bhavana S Vangara; Kelsey Pendleton; Yan Zeng; Yiling Lu; Qiuhong Zhang; Yu Du; Breean R Gilbert; Maria Freilino; Sam Sauerwein; Noah D Peyser; Dong Xiao; Brenda Diergaarde; Lin Wang; Simion Chiosea; Raja Seethala; Jonas T Johnson; Seungwon Kim; Umamaheswar Duvvuri; Robert L Ferris; Marjorie Romkes; Tomoko Nukui; Patrick Kwok-Shing Ng; Levi A Garraway; Peter S Hammerman; Gordon B Mills; Jennifer R Grandis Journal: Cancer Discov Date: 2013-04-25 Impact factor: 39.397
Authors: W J Pattje; E Schuuring; M F Mastik; L Slagter-Menkema; M L Schrijvers; S Alessi; B F A M van der Laan; J L N Roodenburg; J A Langendijk; J E van der Wal Journal: Br J Cancer Date: 2010-05-25 Impact factor: 7.640
Authors: Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron Journal: N Engl J Med Date: 2009-08-19 Impact factor: 91.245
Authors: Y Kokubo; A Gemma; R Noro; M Seike; K Kataoka; K Matsuda; T Okano; Y Minegishi; A Yoshimura; M Shibuya; S Kudoh Journal: Br J Cancer Date: 2005-05-09 Impact factor: 7.640
Authors: Alexandre A B A da Costa; Felipe D'Almeida Costa; Daniel Vilarim Araújo; Marcos Pedro Guedes Camandaroba; Victor Hugo Fonseca de Jesus; Audrey Oliveira; Ana Caroline Fonseca Alves; Carlos Stecca; Larissa Machado; Andrea Cruz Feraz de Oliveira; Thiago Bueno de Oliveira; Ulisses Ribaldo Nicolau; Vladmir Cláudio Cordeiro de Lima Journal: Med Oncol Date: 2018-11-26 Impact factor: 3.064
Authors: Sylwia M Łapińska-Szumczyk; Anna M Supernat; Hanna I Majewska; Jacek Gulczyński; Wojciech Biernat; Dariusz Wydra; Anna J Żaczek Journal: Int J Clin Exp Med Date: 2015-11-15
Authors: Berta Victoria Martinez; Joseph M Dhahbi; Yury O Nunez Lopez; Katarzyna Lamperska; Paweł Golusinski; Lukasz Luczewski; Tomasz Kolenda; Hani Atamna; Stephen R Spindler; Wojciech Golusinski; Michal M Masternak Journal: Oncotarget Date: 2015-08-07
Authors: Xiaoxiao Wang; Xin Cao; Ruifang Sun; Charlene Tang; Alexandar Tzankov; Jun Zhang; Ganiraju C Manyam; Min Xiao; Yi Miao; Kausar Jabbar; Xiaohong Tan; Yuyang Pang; Carlo Visco; Yan Xie; Karen Dybkaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Michael B Møller; Ben M Parsons; Jane N Winter; Miguel A Piris; Shaoying Li; Roberto N Miranda; L Jeffrey Medeiros; Yong Li; Zijun Y Xu-Monette; Ken H Young Journal: Neoplasia Date: 2018-05-04 Impact factor: 5.715
Authors: Anna Starzyńska; Aleksandra Sejda; Paulina Adamska; Giulia Marvaso; Monika Sakowicz-Burkiewicz; Łukasz Adamski; Barbara A Jereczek-Fossa Journal: Arch Med Sci Date: 2020-11-13 Impact factor: 3.318